GILD  Gilead Sciences Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

110.16B

Vuru Grade

92.50/100

Current Price

$82.72
+0.405 (+0.492%)

Growth Price

$163.94
Undervalued by 98.20%

Stability Price

$51.35
Overvalued by 37.92%

Company Metrics

  • P/E 7.061
  • P/S 3.338
  • P/B 8.282
  • EPS 11.714
  • Cash ROIC 49.59%
  • Cash Ratio 1.48
  • Dividend 1.88 / 2.34%
  • Avg. Vol. 9.79M
  • Shares 1.52B
  • Market Cap. 110.16B

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Gilead Sciences Inc. Stock Momentum Hits Extreme Weakness
CML News - 20 hours ago
This is a momentum stock rating analysis for Gilead Sciences Inc. (NASDAQ:GILD) . The company has a one bull momentum rating which indicates extreme weakness.
Gilead Sciences, Inc. (NASDAQ:GILD): Epclusa Approval Reinforces Strong ...
TCC - 22 hours ago
Geoffrey Porges, Leerink Partners analyst offered commentary on Gilead Sciences, Inc. (NASDAQ:GILD) soon after the FDA approved its HCV treatment drug, Epclusa.
What Impact Will Epclusa Have On Gilead Sciences, Inc. (NASDAQ:GILD) Revenue? - Market Exclusive
Why Gilead Sciences, Inc. (GILD), Bank of America Corp (BAC) and Facebook Inc ... - Investorplace.com
Gilead Sciences, Inc. (GILD) Has an Undervalued Pipeline: Leerink Partners
TCC - 21 hours ago
After the approval of Gilead Sciences, Inc.'s (NASDAQ:GILD) hepatitis C treatment “Epclusa” by the Food and Drug Administration, Leerink Partners analyst Geoffrey Porges has weighed in on the stock.
Gilead Sciences, Inc. (NASDAQ:GILD) Analyst Research Summary: - Zergwatch
Gilead Sciences, Inc. (GILD) Rating Reiterated by Leerink Swann - Community Financial News
Gilead Sciences Inc., Pfizer Inc., Celgene Corporation Have Largest Drug Pipelines
CML News - Jun 28, 2016
While looking at the current financial and past financial statements of the established biotechnology and pharmaceutical companies can give us an indication of financial health, it's always going to be about the future for these companies.
Gilead Sciences Stock Is Poised To Soar Due To New HCV Drug Approval
Amigobulls - 3 hours ago
On June 28, Gilead Sciences (NSDQ:GILD) announced that the U.S. Food and Drug Administration had approved Epclusa the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus infection.
Gilead Sciences, Inc. (NASDAQ:GILD) Secures Approval To Market Odefsey In Europe
Market Exclusive - Jun 24, 2016
Gilead Sciences, Inc. (NASDAQ:GILD) has hit another milestone with its HIV drug Odefsey. The European Commission has given its seal of approval for the drug to be marketed in Europe.
Leerink Shines Light on Gilead Sciences, Inc. (GILD) Following R&D Call With ... - Smarter Analyst
Gilead Sciences, Inc. (GILD): The Critical Support Breakdown Trading Level For ... - ETF Daily News
Gilead: All Eyes On FDA This Week
Seeking Alpha - Jun 27, 2016
One big decision that is expected out this week, has the potential to substantially expand Gilead Sciences (NASDAQ:GILD) pipeline of treatments for HCV.
Should You Buy Gilead Sciences Inc?
Amigobulls - Jun 9, 2016
The company's two hepatitus C drugs -- Sovaldi and Harvoni -- have performed miracles in the field, curing 90% of the patients who take them.
Gilead Sciences, Inc. (GILD) Wins A Lost Fight Against Merck & Co., Inc. (MRK) - TCC
Great News For Gilead - Seeking Alpha
Gilead Sciences, Inc: Can HCV Add to Massive Sales Growth?
Bidness ETC - Jun 25, 2016
Gilead Sciences, Inc. (NASDAQ:GILD), the undisputed leader of the fast-expanding hepatitis C treatment market, will continue to see strong growth from its top-selling franchise despite a stagnating trend in the industry.
Company Update (NASDAQ:GILD): Gilead Sciences, Inc. Presents Preliminary Data ...
Smarter Analyst - Jun 20, 2016
Gilead Sciences, Inc. (NASDAQ:GILD) announced data from four pre-clinical and Phase 1 studies evaluating bictegravir (GS-9883), a novel, unboosted, investigational once-daily integrase strand transfer inhibitor (INSTI).